Citi Reiterates Neutral Rating on Arrowhead Pharma (ARWR)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Arrowhead Pharma (ARWR) PT Raised to $29 at Leerink Partners
June 3, 2024 1:33 PM EDTLeerink Partners analyst Mani Foroohar raised the price target on Arrowhead Pharma (NASDAQ: ARWR) to $29.00 (from $27.00) while maintaining a Market Perform rating.... More
Arrowhead Pharmaceuticals (ARWR) Reports Successful Results for Plozasiran from the Phase 3 PALISADE Study
June 3, 2024 7:32 AM EDTArrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from the pivotal Phase 3 PALISADE study of investigational plozasiran in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS), a severe genetic disease with significant unmet need and no FDA approved therapies. PALISADE successfully met the primary endpoint of lowering triglycerides and met all key secondary endpoints,... More
RBC Capital Reiterates Outperform Rating on Arrowhead Pharma (ARWR)
May 30, 2024 6:13 AM EDTRBC Capital analyst Luca Issi reiterated an Outperform rating and $50.00 price target on Arrowhead Pharma (NASDAQ: ARWR)
The analyst comments "We hosted CEO for Boston NDR and he came across as very confident on cardiometabolic (particularly on upcoming FCS data, differentiation to... More
